Less-Known Phosphodiesterase Type 5 Inhibitors – New Solutions for the Therapy of Erectile Dysfunction

Erectile dysfunction (ED) is a serious health problem that directly affects quality of males’ life. In the drug treatment of ED, a group of phosphodiesterase type 5 inhibitors plays an important role (PDE-5), which is the first line of treatment for ED. This article presents the currently available data regarding the parameters of pharmacokinetics, pharmacodynamics and possible adverse events of PDE-5 inhibitors that are not so widely known or are at various stages of clinical trials. Less-known PDE-5 inhibitors, which are presented in the article, include lodenafil, mirodenafil, yokenafil, SLx-2101 and simmerafil.